Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Gastrointestinal Cancers
NCT06596694Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in colorectal cancer (CRC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC) and 1 more, sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 44 months and 2 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
colorectal cancer (CRC)biliary tract cancer (BTC)hepatocellular carcinoma (HCC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06596694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596694.